These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Diagnosis and the current trends in multiple myeloma therapy. Dmoszyńska A Pol Arch Med Wewn; 2008 Oct; 118(10):563-6. PubMed ID: 19112817 [TBL] [Abstract][Full Text] [Related]
3. Targeted therapy in multiple myeloma. Chng WJ; Lau LG; Yusof N; Mow BM Cancer Control; 2005 Apr; 12(2):91-104. PubMed ID: 15855892 [TBL] [Abstract][Full Text] [Related]
4. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778 [TBL] [Abstract][Full Text] [Related]
5. The emerging role of novel therapies for the treatment of relapsed myeloma. Richardson PG; Hideshima T; Mitsiades C; Anderson KC J Natl Compr Canc Netw; 2007 Feb; 5(2):149-62. PubMed ID: 17335684 [TBL] [Abstract][Full Text] [Related]
19. Novel agents in the frontline management of multiple myeloma. Loong HH Hematol Oncol Stem Cell Ther; 2008; 1(4):201-9. PubMed ID: 20058474 [TBL] [Abstract][Full Text] [Related]
20. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials. Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]